TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26901037
Drug: Total Intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Intravenous Anaesthesia with Propofol (TIVA)
Study: 26901163
Drug: Locoregional therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional therapies before sorafenib
Study: 26901163
Drug: Sorafenib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib treatment duration
Study: 26903002
Drug: Early aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early aspirin administration
Study: 26903277
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of ceftriaxone injection followed by 6 days of 400 mg of cefixime per day
Study: 26903311
Drug: Panobinostat (20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat (20-60 mg) and epirubicin (75 mg/m² on day 5) given in 21-day cycles.
Study: 26903311
Drug: Panobinostat (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat (50 mg, MTD) and epirubicin (75 mg/m² on day 5) given in 21-day cycles.
Study: 26904207
Drug: Bronchodilator response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bronchodilator response (BDR)
Study: 26904404
Drug: ASP2215 (novel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP2215 (novel FLT3-inhibitor)
Study: 26904570
Drug: Cisplatin 30
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 30 mg/m(2)/week and paclitaxel 50 mg/m(2)/week for 5 weeks
Study: 26904570
Drug: Cisplatin 40
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 40 mg/m(2)/week for 5 weeks (control arm)
Study: 26907184
Drug: Ertapenem (Empirical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem (Empirical Therapy)
Study: 26907184
Drug: Other carbapenems
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other carbapenems (Empirical Therapy)
Study: 26907184
Drug: Ertapenem (Targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem (Targeted Therapy)
Study: 26907184
Drug: Other carbapenems
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other carbapenems (Targeted Therapy)
Study: 26907630
Drug: CD19 CAR-T-cell
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19 CAR-T-cell therapy
Study: 26908063
Drug: poly(ADP-ribose) polymerase
Normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: poly(ADP-ribose) polymerase inhibitors
Study: 26908089
Drug: Lurasidone (psychotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (psychotropic medication)
Study: 26908748
Drug: Recent oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recent oral sex partners (within the prior 3 months) among men
Study: 26908748
Drug: Oral HPV
Normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HPV infection clearance
Study: 26908756
Drug: FMP2.1/AS01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMP2.1/AS01 vaccine
Study: 26911200
Drug: Extended CRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended CRT (54Gy and 6 cycles of 5FU-based chemotherapy)
Study: 26911200
Drug: Standard CRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CRT (54Gy and 2 cycles of 5FU-based chemotherapy)
Study: 26911408
Drug: FOLFOXIRI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOXIRI plus panitumumab (5-FU, 3,200 mg/m(2), 48-hour continuous intravenous infusion; leucovorin, 200 mg/m(2) i.v.; irinotecan, 125 mg/m(2); oxaliplatin, 85 mg/m(2) i.v.; panitumumab, 6 mg/kg i.v.)
Study: 26911583
Drug: High (>2370
Approvals — FDA: no, EMA: no, PMDA: no
Description: High (>2370 ng/L) and intermediate (806-2370 ng/L) NT-proBNP levels
Study: 26912134
Drug: Selumetinib 75
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib 75 mg bd in combination with Cisplatin (25 mg/m²) and Gemcitabine (1000 mg/m²) administered on days 1 and 8 of a 21-day cycle.
Study: 26913697
Drug: Maintenance lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance lenalidomide (5-10 mg/d for 12 cycles)
Study: 26913697
Drug: Bendamustine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine + rituximab (BR) induction without maintenance therapy
Study: 26918124
Drug: Oral antithrombotic
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antithrombotic drugs
Study: 26919263
Drug: Post-procedure intravenous
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-procedure intravenous antibiotic administration
Study: 26920463
Drug: Epicutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epicutaneous immunotherapy using the Viaskin patch, dosage and duration not available
Study: 26921281
Drug: Adjunctive balloon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive balloon angioplasty
Study: 26922278
Drug: Candidates for
Normalized name: FINLAY-FR-1 anti-SARS-CoV-2 vaccine candidate
DrugBank: FINLAY-FR-1 (DB16524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candidates for LVAD treatment
Study: 26923436
Drug: Sofosbuvir (SOF)
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir (SOF) 400 mg/day with median starting ribavirin (RBV) dose of 800 mg (IQR: 400-1200)
Study: 26923436
Drug: Sofosbuvir (SOF)
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir (SOF) 400 mg/day
Study: 26923925
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) delivered by bachelor-level lay providers (BLPs)
Study: 26923925
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) delivered by PhD-level expert providers (PLPs)
Study: 28288682
Drug: ADA discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADA discontinuation
Study: 26926644
Drug: Clindamycin intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin intravenous dosing regimens (5 mg/kg for ≤32 weeks PMA, 7 mg/kg for 32 to 40 weeks PMA, 9 mg/kg for >40 to 60 weeks PMA) administered every 8 hours
Study: 26926676
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy alone in patients with RS ≤ 11
Study: 26926676
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in patients with RS > 25
Study: 26926676
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in patients with RS 12 to 25
Study: 26927672
Drug: Octanoic acid
Normalized name: Octanoic acid
DrugBank: Caprylic acid (DB04519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octanoic acid (OA) administered in doses ranging from 8 to 128 mg/kg
Study: 26929418
Drug: Shorter regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter regimen using currently available TB drugs
Study: 26929418
Drug: Bedaquiline-containing regimens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedaquiline-containing regimens (all-oral and shortened version)
Study: 26929648
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg IV every 14 days) and Erlotinib (150 mg oral daily)
Study: 26930146
Drug: HPV4 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV4 vaccine (1-3 doses)
Study: 26930527
Drug: Omega-3 arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 arm (930 mg EPA/750 mg DHA + 50 mg/d sertraline)
Study: 26930527
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus placebo arm
Study: 26930627
Drug: Favipiravir (day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Favipiravir (day 0: 6,000 mg; day 1 to day 9: 2,400 mg/d)
Study: 26933422
Drug: Nivolumab (anti-PD-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (anti-PD-1 inhibitor) and RRx-001 (experimental anticancer agent)
Study: 26934750
Drug: Anflu® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anflu® vaccine (2013-14 formulation: H1N1, H3N2, BYAM)
Study: 26936878
Drug: Expressing 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expressing 500 mL/day by day 10
Study: 26936878
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of complete daily records
Study: 26939629
Drug: Convection-enhanced delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convection-enhanced delivery treatment of a therapeutic antibody
Study: 26940080
Drug: Dexmedetomidine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine administered as a bolus of 1 μg/kg over 10 min followed by 1 μg/kg/h infusion, with possible increase to 2 μg/kg/h if necessary.
Study: 26940080
Drug: Lower dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dexmedetomidine dose and shorter sedation time for children younger than 1 year of age.
Study: 26940383
Drug: Early home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early home-based walking program implemented 1-month post-ICD implant.
Study: 26942463
Drug: Enzastaurin 500
Normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin 500 mg orally once daily
Study: 26942886
Drug: Matched cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched cohort (received no drugs predicted to be lack-of-benefit)
Study: 26942886
Drug: Unmatched cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmatched cohort (received at least one drug predicted to be lack-of-benefit)
Study: 26943275
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and paclitaxel chemotherapy
Study: 26944694
Drug: Microcirculatory parameters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcirculatory parameters recorded using sublingual incident dark field microscopy and global flow measurements (oesophageal Doppler and transthoracic echocardiography).
Study: 26944694
Drug: Sequential Organ
Normalized name: argan oil
DrugBank: Argan oil (DB14310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Organ Failure Assessment scores analysis.
Study: 26944863
Drug: Oral LNG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral LNG 1.5 mg plus LNG 52 mg IUD
Study: 26945556
Drug: Colonic confocal
Normalized name: COLON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonic confocal laser endomicroscopy (CLE) after medical treatment escalation
Study: 26945843
Drug: IL-1 receptor
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-1 receptor antagonist (IL-1Ra) + low-dose dexamethasone (20 mg weekly)
Study: 26947173
Drug: Roxadustat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (200 mg)
Study: 26947173
Drug: Roxadustat and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat and Warfarin
Study: 26947199
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg/day, days 1-21 of a 28-day cycle (cohort 1)
Study: 26947199
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg/day continuously (cohort 2)
Study: 26947199
Drug: Lenalidomide 35
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 35 mg/day continuously (cohort 3)
Study: 26948580
Drug: 280 mg
Normalized name: levodopa 280 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 280 mg semagacestat
Study: 26948683
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg dexamethasone suppression test (DST)
Study: 26949390
Drug: Continuous S(+)-ketamine
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous S(+)-ketamine infusion at a rate of 0.3 mg·kg(-1)·h(-1)
Study: 26951043
Drug: RebiSmart(®) for
Approvals — FDA: no, EMA: no, PMDA: no
Description: RebiSmart(®) for self-administering IFN β-1a 44 μg three times weekly
Study: 26951310
Drug: Pembrolizumab 2
Normalized name: pembrolizumab 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 2 or 10 mg/kg every 2 weeks or every 3 weeks
Study: 26951410
Drug: Depot gonadotropin-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot gonadotropin-releasing hormone agonist (GnRHa) leuprolide
Study: 26951627
Drug: Dasatinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (100 mg once daily) combined with chemotherapy
Study: 26951820
Drug: MRKAd5 HIV-1
Normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRKAd5 HIV-1 Gag/Pol/Nef vaccine
Study: 26952006
Drug: Resminostat plus
Normalized name: resminostat
DrugBank: Resminostat (DB12392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resminostat plus sorafenib (n=38); dosages ranged from daily 200 to 600mg resminostat plus 400 to 800mg sorafenib.
Study: 26952006
Drug: Resminostat monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resminostat monotherapy (n=19); dosage was 600mg.
Study: 26952546
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg, given every 3 weeks)
Study: 26957532
Drug: Evidence-based medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medication use in-hospital and at discharge
Study: 26960977
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg adenosine injected into the left atrium
Study: 26960977
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg adenosine injected sequentially after 20 mg
Study: 26960977
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg adenosine injected sequentially after 20 mg
Study: 26960977
Drug: High-dose adenosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adenosine
Study: 26962173
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake of 0.2 to 2.0 g ⋅ kg-1 ⋅ d-1, consumed hourly for 8 hours as an amino acid mixture with egg protein and L-[1-13C]phenylalanine as the indicator amino acid.
Study: 26962173
Drug: Current intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current intake recommendations for dietary protein of 0.66 g ⋅ kg-1 ⋅ d-1 for EAR and 0.8 g ⋅ kg-1 ⋅ d-1 for RDA.
Study: 26962179
Drug: Vitamin B-6
Normalized name: Vitamin B-6 100mg Tablet
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B-6 restriction (0.37 ± 0.04 mg/d)
Study: 26962183
Drug: α-lipoic acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-lipoic acid (LA) 0.3 g/d
Study: 26962183
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 1.3 g/d
Study: 26962189
Drug: Cocoa extract
Normalized name: Cocoa extract
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa extract (1.4 g/d, 645 mg total polyphenols/d)
Study: 26962193
Drug: SQ-LNSs with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ-LNSs with 0 or 10 mg added zinc and placebo tablet
Study: 26965296
Drug: FG-3019 administered
Normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
Approvals — FDA: no, EMA: no, PMDA: no
Description: FG-3019 administered by intravenous infusion every 3 weeks for 45 weeks
Study: 26965794
Drug: Empirical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical treatment with commonly used antimicrobials as per IDSA guidelines
Study: 26965915
Drug: Romidepsin 14
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin 14 mg/m² on days 1, 8, and 15 of six 28-day cycles; maintenance dosing twice per cycle after 12 cycles, and potentially reduced to once per cycle after 24 cycles for those who had received maintenance for ≥6 months.
Study: 26965915
Drug: Romidepsin (continuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romidepsin (continuation of treatment for patients with SD),
Study: 26966027
Drug: ASP3026 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP3026 (oral ALK inhibitor) at doses of 25-800 mg once daily in 28-day cycles
Study: 26966027
Drug: ASP3026 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP3026 (oral ALK inhibitor)
Study: 26966551
Drug: CAU plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAU plus IBD-specific cognitive-behavioural therapy (CBT)
Study: 26966573
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) iron
Study: 26966573
Drug: Overall antianemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall antianemic therapy
Study: 26968374
Drug: Clinical and
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical and laboratory parameters assessed daily for up to 6 days during acute illness and at a follow-up visit 1 week later.
Study: 26968534
Drug: Idelalisib and
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idelalisib and entospletinib combination therapy
Study: 26968708
Drug: EGFR-targeted CAR-T
Normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR-targeted CAR-T cell infusions
Study: 26971081
Drug: Sertraline 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 300 mg/day
Study: 26971081
Drug: Sertraline (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (any dose)
Study: 26971081
Drug: Sertraline 100-200
Normalized name: sertraline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 100-200 mg/day
Study: 26971192
Drug: Drug taper
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug taper
Study: 26971192
Drug: Tapering to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering to no medications
Study: 26971192
Drug: Trials requiring
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trials requiring treatment resistance
Study: 26971488
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of electrographic status epilepticus
Study: 26971680
Drug: Intrathecal injection
Normalized name: BACLOFEN 50 ug in 1 mL INTRATHECAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal injection of autologous bone marrow-derived mesenchymal stromal cells (MSCs) at a median dose of 1.2 × 10(6) MSCs/kg body weight, with 2-3 injections per patient.
Study: 26971692
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 therapy
Study: 26972567
Drug: Bone marrow-derived
Normalized name: Allogeneic human bone marrow-derived mpc
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow-derived endothelial progenitor cells (EPC), administered through the hepatic artery in a single administration.
Study: 26973849
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii (Perenterol forte 250 mg capsules, twice per day for 7 days after antibiotic discontinuation)
Study: 26973849
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo, twice per day for 7 days after antibiotic discontinuation)
Study: 26974526
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg q24h
Study: 26974526
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg q12h
Study: 26974526
Drug: Metformin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin alone (Period 1)
Study: 26974547
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity levels (measured by daily step counts using accelerometry)
Study: 26975937
Drug: Oral mixed-meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mixed-meal tolerance test (OMTT)
Study: 26976424
Drug: Temsirolimus 25
Normalized name: temsirolimus 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus 25 mg intravenously once per week
Study: 26976424
Drug: Temsirolimus 75
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus 75 mg intravenously once per week
Study: 26976424
Drug: Temsirolimus 25
Normalized name: temsirolimus 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus 25 mg and 75 mg cohorts
Study: 26976799
Drug: ombitasvir co-formulated
Normalized name: Ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ombitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir for 12 weeks (with ribavirin for genotype 1a patients)
Study: 26976799
Drug: ombitasvir co-formulated
Normalized name: Ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ombitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir for 12 weeks (without ribavirin for genotype 1b patients)
Study: 26976799
Drug: Ribavirin therapy
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin therapy